Prestige Consumer Healthcare’s (PBH) “Hold” Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group restated their hold rating on shares of Prestige Consumer Healthcare (NYSE:PBH) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $76.00 price objective on the stock, up from their prior price objective of $70.00.

Separately, DA Davidson upped their price objective on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a buy rating in a research report on Wednesday, August 28th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $94.20.

Prestige Consumer Healthcare Trading Down 0.0 %

PBH stock opened at $71.32 on Tuesday. The business has a fifty day simple moving average of $71.21 and a 200-day simple moving average of $69.65. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a 52 week low of $56.34 and a 52 week high of $75.80. The company has a market cap of $3.54 billion, a price-to-earnings ratio of 17.10, a PEG ratio of 2.04 and a beta of 0.48.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm had revenue of $267.10 million during the quarter, compared to analysts’ expectations of $260.54 million. During the same period in the prior year, the company earned $1.06 EPS. The firm’s revenue was down 4.4% on a year-over-year basis. On average, equities research analysts expect that Prestige Consumer Healthcare will post 4.42 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sanctuary Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the second quarter worth about $1,095,000. Brandes Investment Partners LP increased its stake in shares of Prestige Consumer Healthcare by 9.0% in the second quarter. Brandes Investment Partners LP now owns 165,293 shares of the company’s stock valued at $11,447,000 after purchasing an additional 13,643 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the period. Algert Global LLC increased its stake in shares of Prestige Consumer Healthcare by 50.7% in the second quarter. Algert Global LLC now owns 14,873 shares of the company’s stock valued at $1,024,000 after purchasing an additional 5,003 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Prestige Consumer Healthcare by 0.8% in the second quarter. The Manufacturers Life Insurance Company now owns 543,401 shares of the company’s stock valued at $37,413,000 after purchasing an additional 4,305 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.